BridgeBio Q3 2026 Earnings Call - BRIDGEBIO PHARMA INC

Financial Performance:

• Total Q3 2026 revenue reached $353.2 million, up from $120.7 million year-over-year, driven by a $75 million one-time licensing milestone from Bayer and a 134% increase in Atruby net product revenue.
• Atruby U.S. net product revenue was $253.2 million (up 14% sequentially and 134% YoY); royalty revenue was $20.5 million.
• Total operating expenses increased to $344.4 million due to investments in Atruby and preparations for three upcoming launches; this resulted in an $11.6 million operating loss, a significant improvement from the $145.2 million loss in Q3 2025.
• Cash, cash equivalents, and marketable securities stood at $1.5 billion as of September 30, 2026, the company's strongest balance sheet to date.
• Management anticipates operating losses averaging $92 million per quarter for the full year 2026, with expectations of operating leverage expansion and path to break-even in 2027 as Atruby scales.

Guidance and Future Outlook:

• Three product launches are scheduled within the next seven months: BBP418 (Nov 27 PDUFA), Infragratinib (Feb 4 PDUFA), and Incalorette (May 8 PDUFA), all receiving FDA priority review.
• Atruby is annualizing over $1 billion in the U.S. and exceeds that globally; management projects peak year sales of $4 billion for the Atruby franchise and an additional $4 million across the three new brands.
• BBP418 submission to EMA is targeted for the first half of 2028, contingent on 36-month data expected in late 2027.
• Infragratinib and Incalorette MAA submissions to EMA have been made, with EU approvals anticipated in the second half of 2027.
• The RECLAIM-HP phase 3 trial for chronic hypoparathyroidism is enrolling with top-line results expected in 15 months.
• Management expects operating margins to improve throughout 2027, leading to standalone profitability for all four brands by 2028.

Business Segments and Product Lines:

• Atruby (ATTR-CM): Leading brand in Europe; growing first-line share with strong real-world evidence showing 18-43% risk reductions vs. Tafamidis. Dosed first patient in ASCEND-ATTR (Phase 3b/4) and nominated next-gen antibody BBP717 for IND in 2027.
• BBP418 (LGMD2I): Phase 3 data (4-5 mo) showed improvements in ambulation and cardiac function (troponin normalization in 100% vs 40% placebo); 500+ U.S. patients identified; 90% of MDA centers contacted.
• Infragratinib (Achondroplasia): Only oral therapeutic in development; Propel 3 data showed height velocity, proportionality, and 38% reduction in ear infections; Phase 2-3 pediatric study (Xcell) expanding dose range.
• Incalorette (ADH-1): First therapy specifically for ADH-1; demonstrated kidney function improvement (eGFR +11 vs +3) and symptom relief; Phase 3 RECLAIM-HP for chronic hypoparathyroidism started enrollment.
• Commercial Infrastructure: Field teams fully staffed and deployed for all three upcoming launches; utilizing AI and patient-facing "TypeHype" campaigns to identify undiagnosed patients.

Market and Competitive Landscape:

• Atruby is solidly in second place for new patient starts in the U.S. and first-line setting; real-world evidence continues to differentiate it from Tafamidis (Tafamidis' competitors face pressure as Atruby gains share).
• In Europe, the franchise (via partner Bayer) is the leading brand, validating a "level playing field" reimbursement environment.
• Atruby is the only near-complete stabilizer; data suggests silencers do not add benefit on top of stabilization (CardioTransform results), closing the door on combination therapy as the standard of care.
• Infragratinib faces a competitor (Vindamax/Pfizer) via citizen's petition regarding neurocognitive safety; management dismisses the petition as hypocritical and baseless, noting no impact on review timeline or label.
• Market share growth is being driven by expanding into the "long tail" of 60% of prescribers who have not yet tried Atruby.

Risks and Challenges:

• Reimbursement & Policy: Potential changes to ASP under IRA Part B could impact sales, though impact on Atruby (Part D) is expected to be neutral or positive; payers may restrict competitor drugs but Atruby remains accessible with >90% appeal approval rates.
• Competitive Actions: Competitors are targeting the "long tail" of prescribers; Pfizer (Vindamax) and others are monitoring launch metrics closely.
• Regulatory: PDUFA dates are firm, but success depends on successful commercial execution and payer access for the three new launches.
• Clinical: BBP418 is currently based on interim data; European regulators require 36-month data, extending the EU timeline compared to the US.

Management Commentary and Tone:

• Tone is highly confident and execution-focused, describing the quarter as a "pivotal moment" with three upcoming launches.
• Management emphasizes reducing information asymmetry, arguing that quarterly revenue data is a true signal of valuation while R&D updates are less frequent.
• Strong emphasis on "first-line" market dominance and the "stabilizer-first" paradigm for ATTR-CM.
• Explicit commitment to capital discipline, prioritizing operational funding before M&A or share buybacks, noting a recent buyback in September.

Analyst Questions and Answers:

• Atruby Growth: Management confirmed $25-30 million sequential revenue base for near-term quarters, driven by first-line share gains and expanding prescriber base.
• Reimbursement: Clarified that proposed ASP changes affect Part B (injectables), not Part D (Atruby oral), negating negative impact.
• Capital Allocation: Confirmed focus is on executing current launches and internal pipeline (Hypopara, BBP717) rather than immediate M&A, though Gondola progress is watched.
• BBP418 Europe: EU submission delayed to H1 2028 because regulators require full 36-month data, unlike the US which allowed approval based on interim data.
• Incalorette Market: Chronic hypoparathyroidism target market estimated at 200,000 patients (vs. 25,000 for ADH-1), with specific interest from post-surgical patients, those with bone density issues, and needle-averse patients.
• Infragratinib Safety: Reiterated that citizen's petition concerns are based on flawed mouse models (knockout vs. partial inhibition) and clinical data shows no CNS effects.

Other Key Points:

• Real-world evidence (Komodo and Epic Cosmos studies) consistently shows Atruby reducing clinical worsening and hospitalization risks significantly compared to Tafamidis within the first month of treatment.
• Atruby demonstrated 54% of patients with improved left ventricular systolic function at 30 months vs 20% placebo.
• BBP418 restored alpha-dystroglycan to asymptomatic carrier levels, a unique "restorative" rather than "slowing" mechanism.
• The company is leveraging AI and genetic testing to drive patient identification and education for rare disease indications.
• Incalorette showed 100% of participants reported symptom improvement (fatigue, spasms, brain fog) vs 46% on standard of care.